Only in Titles

           Search results for: c-erbB-2 Oncoprotein    

paperclip

#26985869   // Save this To Up

Expression of MIF and c-erbB-2 in endometrial cancer.

The aim of the present study was to investigate the expression of c-erbB-2 and macrophage migration inhibitory factor (MIF) in endometrial cancer and to elucidate the significance of the early diagnosis and prognosis of endometrial cancer. The gene copy number of c‑erbB‑2 and MIF was characterized by reverse transcription quantitative polymerase chain reaction and the reactivity was assessed by immunohistochemistry in 70 patients using a polyclonal antibody, and evaluated semiquantitatively according to the percentage of cells demonstrating membranous or diffuse cytoplasmic staining. A correlation between age, tumor stage, grade, myometrial invasion and lymph node metastasis was observed. The mRNA expression of c‑erbB‑2 and MIF was high in endometrial carcinoma. The positive expression rate of MIF protein in normal endometrium, atypical hyperplasia and endometrial carcinoma significantly increased along with the degree of aggravation of the disease by 20 (3/15), 45 (9/20) and 70% (35/50), respectively. The positive expression of MIF and c‑erbB‑2 was highest in endometrial cancer and a significantly higher level of protein was observed in tumors at stage I, stage G1, with a depth of myometrial invasion <0.4 cm and no lymph node metastasis. The protein expression of c‑erbB‑2 in endometrial cancer was higher in tumors at the G2‑3 phase, clinical stage III‑IV, lymph node metastasis, and had no association with the depth of myometrial invasion and age. MIF and c‑erbB‑2 were correlated with the occurrence and the development of endometrial cancer, and thus can be used for the early diagnosis and prognosis of endometrial cancer. The present study laid the foundation for identifying new treatments for endometrial cancer.

2184 related Products with: Expression of MIF and c-erbB-2 in endometrial cancer.

Prostate cancer, hyperpla Endometrial cancer test t Endometrial cancer tissue Uterus cancer test tissue includes 10 x reaction bu XL-765 (SAR-245409) Mecha Endometrium cancer test t Cancer Apoptosis Phospho- Kidney cancer survey tiss Eosin 5 isothiocyanate, R Basic module Infinicyt v Stomach cancer tissue arr

Related Pathways

paperclip

#25558642   // Save this To Up

The expression of EGFR, cerbB2, p16, and p53 and their relationship with conventional parameters in squamous cell carcinoma of the larynx.

To investigate the expression of epidermal growth factor receptor-HER1 (EGFR), cerbB2 (HER2), p16, and p53, as well as the relationship of the expression of these genes with conventional parameters in squamous cell carcinoma (SCC) of the larynx.

2961 related Products with: The expression of EGFR, cerbB2, p16, and p53 and their relationship with conventional parameters in squamous cell carcinoma of the larynx.

Esophageal squamous cell Cervix squamous cell carc Esophagus squamous cell c Skin squamous cell carcin Esophagus squamous cell c Esophageal squamous cell Oral cavity squamous cell Esophagus squamous cell c Lung squamous cell carcin FDA Standard Frozen Tissu Skin squamous cell carcin Lung large cell carcinoma

Related Pathways

paperclip

#25520097   // Save this To Up

Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?

We aimed to evaluate the effects of hormone receptor, HER2, and epidermal growth factor receptor (EGFR) expression on epithelial ovarian cancer (EOC) prognosis and investigate whether or not phenotypic subtypes might exist.

1463 related Products with: Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?

Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep anti-EGFR (Phospho-Tyr119 Goat Anti-Human Neuropept interleukin 17 receptor C Rabbit Anti-Insulin Recep

Related Pathways

paperclip

#24947414   // Save this To Up

Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.

Our purpose was to investigate the expression pattern of BRCA1 protein in sporadic breast carcinomas, as well as the clinicopathological and prognostic value of its subcellular localizations. Immunohistochemistry was performed on paraffin embedded tissue specimens from 111 sporadic, invasive breast carcinomas to detect the expression of the proteins BRCA1, ER, PR, erbB2, p53 and Ki67. BRCA1 protein was detected in the nuclei and the cytoplasm of the tumor cells. Nuclear BRCA1 immunoreactivity showed no relation with the classic clinicopathological markers and the expression of cerbB2, p53 and Ki67. Reduced expression of nuclear BRCA1 protein was found to exert an independent favorable impact on both the overall and relapse-free (RF) survival of the patients (p=0.019 and p=0.043, respectively). Cytoplasmic BRCA1 was associated with none of the classic histomorphological indices, except from the lymph node metastasis, with which its relation was found to be inverse (p=0.05), prolonging the RF survival of the patients (p=0.05). Our findings suggest that BRCA1 protein depicts different prognostic significance, according to its subcellular distribution. Nuclear detection of the protein was associated with a worse prognosis, while the cytoplasmic one was related to fewer recurrences as a result of fewer lymph node metastases.

2550 related Products with: Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.

Ofloxacin CAS Number [824 BRCA1 (Phospho Ser1524) High density breast invas Breast cancer, adjacent a Rabbit Anti-BRCA1 BAP1 Po BRCA1 (Ab 1423) Breast tumor survey tissu Breast cancer and normal Human Breast Cancer Antig Monoclonal Anti Breast Ca Breast tumor survey tissu Breast invasive ductal ca

Related Pathways

paperclip

#24065467   // Save this To Up

The importance of COX-2 expression as prognostic factor in early breast cancer.

A number of studies have been carried out, showing that the risk for breast carcinoma is decreased in those using non-steroidal anti-inflammatory drugs (NSAIDs). Increased cyclooxygenase-2 (COX-2) level is considered as a factor indicating poor prognosis and responsible for angiogenesis, increased cellular proliferation, apoptotic defect and aromatase enzyme induction. For this reason the level of COX-2 might have a prognostic and predictive value in breast cancer as well. This question has become the basis of the present study.

2730 related Products with: The importance of COX-2 expression as prognostic factor in early breast cancer.

Breast cancer tissue arra Breast cancer tissue arra ER Immunohistochemistry c MultiGene Gradient therm Breast cancer tissue arra Prostate cancer, hyperpla Breast cancer test tissue Breast cancer test tissue Breast cancer tissue arra Breast cancer and normal Breast cancer tissue arra Breast cancer tissue arra

Related Pathways

paperclip

#23539741   // Save this To Up

Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship.

We evaluated pathological features of the ductal carcinoma in situ component of 241 triple negative invasive breast cancers.

1307 related Products with: Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship.

Breast invasive ductal ca High density (188 cases 2 Breast invasive ductal ca Breast invasive ductal ca Breast invasive ductal ca Breast invasive ductal ca Breast invasive ductal ca Human breast invasive duc Breast invasive ductal ca Her-2 IHC Bio-marker cont High density breast invas Breast invasive ductal ca

Related Pathways

paperclip

#23420345   // Save this To Up

The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.

Although some evidence has been documented on EGFR/PI3K mediation of Akt activation in breast cancers, ILK and DNA-PK have not been investigated so far. The aim of this study was to analyze the expression of phosphorylated Akt (pAkt) in breast cancer, with respect to its upstream regulators. The immunostaining of pAkt (Ser473) in 70 invasive breast cancers revealed that status of CerbB2 could play a major role in Akt phosphorylation, while ILK was also involved in the stimulated level of pAkt. The results would provide an important clue for the activation of Akt and potential targeted therapy in breast cancer.

1625 related Products with: The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.

Human breast invasive duc Breast cancer test tissue FDA Standard Frozen Tissu Breast cancer tissue arra Breast cancer tissue arra Top 4 types of cancer (co Breast invasive ductal ca Breast cancer tissue arra MultiGene Gradient therm Breast invasive ductal ca Middle advanced stage bre Breast cancer test tissue

Related Pathways

paperclip

#23337939   // Save this To Up

Antiproliferative activity of daidzein and genistein may be related to ERα/c-erbB-2 expression in human breast cancer cells.

In this study, we investigated the antiproliferative activity of the isoflavones daidzein and genistein in three breast cancer cell lines with different patterns of estrogen receptor (ER) and c‑erbB‑2 protein expression (ERα‑positive MCF‑7 cells, c‑erbB‑2‑positive SK‑BR‑3 cells and ERα/c‑erbB‑2‑positive ZR‑75‑1). After treatment at various concentrations (1‑200 µM for 72 h), the effect of daidzein and genistein on the proliferation of different cell types varied; these effects were found to be associated with ERα and c‑erbB‑2 expression. Daidzein and genistein exhibited biphasic effects (stimulatory or inhibitory) on proliferation and ERα expression in MCF‑7 cells. Although 1 µM daidzein significantly stimulated cell growth, ERα expression was unaffected. However, genistein showed marked increases in proliferation and ERα expression after exposure to <10 µM genistein. Notably, the inhibition of cell proliferation by 200 µM genistein was greater compared to that by daidzein at the same concentration. Daidzein and genistein significantly inhibited proliferation of SK‑BR‑3 and ZR‑75‑1 cells in a dose‑dependent manner. In addition, ERα and c‑erbB‑2 expression was reduced by daidzein and genistein in both SK‑BR‑3 and ZR‑75‑1 cells in a dose‑dependent manner. However, the effect of genistein was greater compared to that of daidzein. In conclusion, the isoflavones daidzein and genistein showed anti‑breast cancer activity, which was associated with expression of the ERα and c‑erbB‑2 receptors.

1984 related Products with: Antiproliferative activity of daidzein and genistein may be related to ERα/c-erbB-2 expression in human breast cancer cells.

Human breast invasive duc MarkerGeneTM in vivo lacZ Breast cancer tissue arra Breast cancer tissue arra Breast adjacent normal ti Mouse Anti-Human Interleu Breast cancer and matched Breast cancer and normal Breast disease spectrum t Human Breast Cancer Antig Prostate cancer, hyperpla Inhibin beta-A antibody S

Related Pathways

paperclip

#21649466   // Save this To Up

Clinical implications for girdin protein expression in breast cancer.

Girdin is highly expressed in breast carcinomas. Suppression of Girdin inhibited breast cancer cell migration. However, the clinical implications of Girdin as a marker are still unclear. Here we examined 80 breast cancer specimens using immunohistochemistry. Overall, positive Girdin staining was 41.25% in all of the cases. Girdin was strongly expressed in tumors of CerbB2-positive breast cancers (p < .05). Cases with both CerbB2- and Girdin-positive expression had a higher histological grade than the others. These findings indicated the closed relationship between breast cancer progression and Girdin expression. Girdin together with CerbB2 might be a new potential marker for breast cancers.

1656 related Products with: Clinical implications for girdin protein expression in breast cancer.

Breast cancer tissue arra Late stage breast cancer Breast adjacent normal ti Breast cancer and matched Breast cancer test tissue Breast cancer test tissue Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Middle advanced stage bre Breast cancer test tissue

Related Pathways

paperclip

#20591915   // Save this To Up

Application of a novel and low cost technique to construct paraffin tissue microarrays out of paraffinised needle biopsy specimens from patients with breast cancer.

Paraffin tissue microarrays (TMAs) are a well accepted tool in pathology for high throughput molecular profiling, quality control and clinicopathological trials. No reports on TMAs constructed from paraffinised needle biopsy specimens (PNBSs) derived from patients with breast cancer can be found in the literature. PNBSs are sometimes the only source for tumour characterisation important for treatment.

1143 related Products with: Application of a novel and low cost technique to construct paraffin tissue microarrays out of paraffinised needle biopsy specimens from patients with breast cancer.

Breast cancer tissue arra Breast cancer tissue arra Breast cancer mid density Breast cancer tissue arra Breast cancer membrane pr Breast cancer and normal Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer (IDC) tissu Middle advanced stage bre Breast cancer tissue arra

Related Pathways